scholarly journals Paroxetine induced bruxism, treated with Buspirone : An unexplored entity

2014 ◽  
pp. 29-31
Author(s):  
Seshadri Sekhar Chatterjee ◽  
Arnab Maji ◽  
Nitu Mallik

SSRI are the widely prescribed first line drugs for depression and as depression very commonly presents with insomnia SSRI are good at improving the sleep problems also. But though rare the occurrence of sleep related side effects like bruxism,it may cause significant distress and cause of nonadherence which easily may be overlooked. In this case we report a case of Paroxetine induced bruxism and subsequently treated with withdrawing the drug and buspirone. Though the aetiology of such bruxism remained unclear, the imbalances in dopaminergic and serotonergic activities in the central nervous system is mostly implicated.Key Words : Bruxism, Escitalopram, Parafunctional activity, Selective Serotonin Reuptake Inhibitors

2003 ◽  
Vol 33 (3) ◽  
pp. 295-297 ◽  
Author(s):  
Kai-Lin Huang ◽  
Shih-Jen Tsai

Premenstrual dysphoric disorder (PMDD), a menstruous dysfunction, is characterized by profoundly depressed mood, and studies have shown that antidepressants are effective for PMDD. The authors describe a case of PMDD who was initially treated with selective serotonin reuptake inhibitors. Due to intolerable gastrointestinal side effects with selective serotonin reuptake inhibitors, St. John's wort (900 mg/day) was substituted and much improvement in PMDD symptoms was noted for at least five-month follow-up. The authors propose that St. John's wort could be an alternative medication for PMDD, especially for patients experiencing intolerable side effects with selective serotonin reuptake inhibitors.


1995 ◽  
Vol 25 (3) ◽  
pp. 239-248 ◽  
Author(s):  
Winston W. Shen ◽  
Jeffrey H. Hsu

Objective: After the advent of selective serotonin reuptake inhibitors on the U.S. market in 1988, American psychiatrists have been faced with more choices of antidepressants for the treatment of depression. The prescribing of SSRIs has been increasing in popularity because they are easily titrated by the physicians and tolerated by patients. However, the SSRI use is frequently associated with female sexual dysfunction. The aim of this study was to describe these SSRI-associated female sexual side effects. Methods: In a retrospective series, clinic records of 110 female SSRI-treated outpatients were reviewed for loss of or decreased libido, orgasmic disturbances (anorgasmia or delayed orgasm), as well as clinical management patterns to alleviate sexual side effects. Results: Twenty-one fluoxetine-, nine paroxetine-, and five sertraline-treated cases with female sexual inhibition were identified. The fates of SSRI-associated sexual adverse effects and clinical managements of restoring these side effects were described. Conclusions: With some limitations in interpreting the data, the findings of this study suggest that SSRI-associated female sexual dysfunction occurs at a higher rate than we previously thought, equal potentials in implicating female sexual side effects among three SSRIs, and the absence or the low incidence of female sexual adverse effects from bupropion, and that these side effects can be managed by waiting for a spontaneous remission, dosage reduction of SSRIs, substitution with bupropion and other antidepressants, or the use of an antidote.


Sign in / Sign up

Export Citation Format

Share Document